<DOC>
	<DOCNO>NCT00607477</DOCNO>
	<brief_summary>The purpose study describe length time extent blood pressure response minoxidil hydralazine among cancer patient difficult-to-treat vascular endothelial growth factor ( VEGF ) inhibitor treatment induced hypertension .</brief_summary>
	<brief_title>Pilot Study Treatment Vascular Endothelial Growth Factor ( VEGF ) Signaling Pathway Inhibitor-Induced Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Minoxidil</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>Ongoing treatment malignancy University Chicago agent recognize , specific inhibition VEGF , VEGFreceptors , downstream signal molecule specific intention inhibit signal pathway . These agent include limited : bevacizumab ( Avastin™ ) , sorafenib ( Nexavar™ ) , sunitinib ( Sutent™ ) , axitinib ( AG013736 ) , AZD 2171 . Treatment hypertension least 2 antihypertensive medication blood pressure remain great 140/90 mmHg . Stable management toxicity cancer treatment Expected continue current cancer treatment least 4 week 18 year old Ability understand willingness sign write informed consent document prior study specific procedure . Concurrent use hematopoietic supportive treatment erythropoietin congener . Current uncontrolled toxicity due cancer treatment . Patients known contraindication hydralazine minoxidil therapy . Any reading systolic blood pressure &gt; 200 mmHg diastolic blood pressure &gt; 120 mmHg four ( 4 ) week prior screen . Use either minoxidil hydralazine six ( 6 ) month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>